Drugs / autologous dendritic cells
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03546426 | Dec 2019 → Jan 2027 expected | malignant mesothelioma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02840123 | Jun 2016 → Mar 2019 | diffuse intrinsic pontine glioma | Fundació Sant Joan de Déu | Unknown | No outcome recorded |
| Phase 1 | NCT00514189 | Jul 2007 → Dec 2009 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00576641 | May 2007 → Jan 2010 | brain stem glioma, glioblastoma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00185874 | Jan 2004 → Oct 2007 | liver cancer | Stanford University | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00014131 | Nov 2001 → Dec 2009 | kidney cancer | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00010127 | Nov 2000 → Mar 2003 | prostate cancer | Duke University | Terminated | No outcome recorded |
| Phase 1/25 trials · 1 missed | ||||||
| Phase 1/2 | NCT03152565 | Mar 2018 → Jun 2019 | colorectal carcinoma | Grupo Espanol Multidisciplinario del Cancer Digestivo | Completed | Missed primary |
| Phase 1/2 | NCT03085966 | Feb 2017 → Oct 2019 | castration-resistant prostate carcinoma | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02766049 | Feb 2010 → May 2014 | HIV infectious disease | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00637117 | Jul 2008 → Mar 2010 | lymphoma | Baylor Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00053391 | Oct 2002 → Jun 2005 | cutaneous melanoma | University Hospital Erlangen | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07202611 | Dec 2022 → Sep 2025 overdue | non-small cell lung carcinoma | National Taiwan University Clinical Trial Center | Recruiting | No outcome recorded |
| Phase 2 | NCT01734564 | Nov 2012 → Dec 2016 | neoplasm | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT01347034 | Jan 2011 → Aug 2013 | soft tissue sarcoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01006044 | Oct 2009 → Aug 2014 | glioblastoma | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT00334776 | Oct 2003 → Jun 2005 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00006113 | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00005956 | Feb 2000 → Aug 2001 | breast cancer, gastric cancer, ovarian cancer | Duke University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02677155 Background | Jan 2016 → Feb 2021 | follicular lymphoma | Oslo University Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous dendritic cells | “administration of autologous dendritic cells via axillary lymph node injection” NCT07202611 ↗19“Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56” NCT03152565 ↗ “Autologous dendritic cells (DC) are known to activate other immune cells” NCT03085966 ↗ “Autologous dendritic cells (3x10e7)” NCT02766049 ↗ |
| Known as | ADC | “Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56” NCT03152565 ↗ |
| Known as | DCs | “Dendritic cells (DCs) have the ability to activate adaptive immune functions.” NCT07202611 ↗ |
| Action | Deplete | “A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells” NCT00005956 ↗ |
| Modality | Cell therapy | “Vaccines consisted of immature, cultured DC (n = 3), mature cultured DC (n = 3), or mature Flt3-ligand mobilized peripheral blood DC (n = 1) loaded with ICD” PMID 17822557 ↗ Sep 2007 |
| Route | Subcutaneous | “The pulsed DC are administered subcutaneously (SQ) and intradermally” NCT00005956 ↗ |
| Target | ERBB2 | “cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses” PMID 17822557 ↗ Sep 2007 |